Alexander Gutmans

Alexander Gutmans

Partner
Dr. iur., LL.M., Attorney at Law and Notary

Location

Basel

Contact

Direct phone: +41 58 658 14 51
alexander.gutmans@walderwyss.com

Curriculum Vitae

PDF download

Alexander Gutmans is a partner at Walder Wyss since 2014. He advises national and international clients in the fields of commercial and corporate law, mergers & acquisitions, private equity, venture capital and financings as well as in the field of health care and life sciences in contractual and regulatory matters. As a notary of the canton Basel-Stadt he accompanies his clients in commercial register and real estate register transactions as well as German notarisations. Alexander Gutmans is also active as board member.

Born in 1967, Alexander Gutmans studied at the university of Basel (lic. iur. 1990; Dr. iur. 1995) and Lausanne an received a master’s degree from Yale Law School (LL.M. 1996). In 1993 Alexander Gutmans was admitted as attorney at law and in 2002 as notary. He started his professional career as legal counsel at Sandoz AG and after an assignment as foreign associate with an American law firm in New York he worked during 15 years as a lawyer for a leading Swiss law firm with offices in Basel, Bern and Zurich, during the last 11 years as a partner.

Alexander Gutmans‘ professional work languages are German and English. He also speaks French.

Oversubscribed USD 152 Million Series B Financing Round of Vaderis Therapeutics

Walder Wyss advises UVC Partners as lead investor in USD 24 million financing round of Metafuels AG

NUCLIDIUM Closes CHF 79 Million (EUR 84 Million) Series B Financing to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform

Granite Bio Debuts With USD 100 Million of Capital

Walder Wyss advised RhyGaze AG on USD 86m Series A Financing Round

SixPeaks Bio AG debuts with USD 110 million in Funding

Pierre Fabre Laboratories acquires Vertical Bio AG

Alentis Therapeutics Closes USD 105m Series C Funding

Versant Ventures launches Vector BioPharma with USD 30m Series A

ImmunOs Therapeutics Raises USD 74 Million Series B Financing Round

Engimmune Therapeutics raises CHF 15.5m in Seed Financing

Versant Ventures launches Cimeio Therapeutics with USD 50m Series A

kooky secures financing in the amount of EUR 6 million

GlycoEra CHF 45m Series A Financing

Alentis Therapeutics raises USD 67m in Series B Financing

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion

Noema Pharma CHF 54m Series A Financing

Synendos Therapeutics CHF 20m Series A Financing

VectivBio USD 110m Crossover Financing

Monte Rosa Therapeutics USD 96 million Series B Financing

Recognitions


Subscribe to newsletter